Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives
Beverly G Tchang1, Alpana P Shukla, Louis J Aronne
1Weill Cornell Medical College, Comprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism , 1165 York Avenue, New York, NY, 10065 , USA ljaronne@med.cornell.edu.
Expert Opinion on Biological Therapy
|June 12, 2015
Summary
Metreleptin is approved for generalized lipodystrophy and shows promise for other leptin-related conditions like familial partial lipodystrophy and obesity. Further research is needed to address safety concerns for broader applications.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Generalized lipodystrophy is characterized by leptin deficiency, leading to the approval of metreleptin as hormone replacement therapy.
- Leptin abnormalities are also implicated in familial partial lipodystrophy (FPLD), non-alcoholic fatty liver disease (NAFLD), and obesity.
- Metreleptin presents a potential therapeutic strategy for these conditions, including the widespread epidemic of obesity.
Purpose of the Study:
- To review the physiology of leptin.
- To discuss the pharmacologic properties of metreleptin (recombinant methionyl human leptin).
- To examine evidence for metreleptin's efficacy, safety, and future research directions in various lipodystrophic and metabolic conditions.
Main Methods:
- Literature review of existing clinical trials and research on metreleptin.
- Analysis of the physiological role of leptin and its pharmacologic properties.
- Evaluation of safety data and immunogenicity concerns.
Main Results:
- Metreleptin is approved for generalized lipodystrophy.
- Clinical trials are ongoing to assess metreleptin's efficacy in FPLD, HAL, and NAFLD.
- Emerging data suggest a potential therapeutic role for metreleptin in obesity.
Conclusions:
- Metreleptin's approval marks a starting point for its use in other metabolic diseases.
- Safety and immunogenicity remain key challenges for expanding metreleptin's indications.
- Further advancements in biologic compatibility are necessary for broader therapeutic approval.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:24Overview of Lipid Metabolism
7.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
401
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
401
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:28Insulin: The Receptor and Signaling Pathways
6.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.2K